About the job
ABOUT US
In the United States, over 9 million individuals are immunocompromised, with nearly half a million facing severe risks due to COVID-19. This group includes patients who have undergone stem cell and solid organ transplants, as well as those battling hematologic cancers.
At Invivyd, Inc., we are deeply committed to addressing these challenges. Each day, we strive to deliver innovative protection against serious viral infectious diseases, starting with SARS-CoV-2. Our proprietary integrated technology platform is industry-leading, enabling us to assess, monitor, develop, and adapt to create top-tier antibodies.
In March 2024, we received emergency use authorization (EUA) from the U.S. FDA for one of our monoclonal antibody (mAb) candidates, marking a significant milestone in our innovation journey.
In October 2025, the FDA approved our Investigational New Drug (IND) application, allowing us to proceed with the REVOLUTION clinical program, focused on VYD2311—a monoclonal antibody alternative to vaccines for COVID-19 prevention.
Join us in making a meaningful impact. Be part of Invivyd.
Location: East (100% Remote)

